Director Timothy Scannell sold 5,000 PODD shares at $225.84 on 2024-09-10 (post-transaction holdings: 30.6K shares, -14.1%)
Timothy Scannell, a Director, sold 5,000 shares (14.1% of his pre-transaction holdings) at $225.84 on 2024-09-10 at a price very close to the current 52-week high of $227.73. The stock has appreciated 21.1% over the past 30 days and 12.8% over 90 days. Notably, his prior sale at this ticker on 2024-06-10 showed a +12.7% 90-day return—meaning the stock rose after his last sale, indicating poorlyy-timed exits by the traditional insider-selling framework. Insulet's fundamentals show strong performance with annual revenue growth of +30.0%, quarterly revenue of $488.5M, and net income of $188.6M, though the P/E of 40.38 reflects a premium valuation typical of high-growth medical device firms. This current sale occurs at near-peak pricing within the 52-week range, representing a discrete disposal of a material portion of his stake.